CymaBay Therapeutics to Participate in Two Upcoming Investor Conferences

Download as PDF

NEWARK, CA -- (Marketwired) -- 10/15/14 -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) today announced that senior management will participate in the following upcoming investor conferences.

Credit Suisse 2014 Healthcare Conference
Date: November 10-13, 2014
Location: Arizona Biltmore, Phoenix

Stifel 2014 Healthcare Conference
Date: November 19, 2014
Location: New York Palace Hotel, New York
Presentation: 4:10pm -- 4:40pm

A live webcast of the presentation to be made at the Stifel 2014 Healthcare Conference will be available through the investor relations section of the CymaBay website, www.cymabay.com. Following the live webcast, a replay will be available through the same section for 90 days.

About CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company developing breakthrough therapies to treat metabolic and rare diseases with high unmet need. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in Phase 2a gout studies. In gout patients, arhalofenate is intended to prevent painful attacks in joints while at the same time promoting excretion of serum uric acid (sUA) by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. The company has two other product candidates -- MBX-8025 and MBX-2982. MBX-8025 is a potent, selective, orally active PPAR-δ agonist. A Phase 2 study of MBX-8025 in patients with mixed dyslipidemia has established that it has an anti-atherogenic lipid profile that may be useful in the treatment of a wide variety of indications currently under evaluation. MBX-2982 is a GPR-119 agonist that has been shown to lower glucose in patients with type 2 diabetes.

For additional information about CymaBay visit www.cymabay.com.

Contact:
Sujal Shah 
CymaBay Therapeutics, Inc. 
(510) 293-8800
investors@cymabay.com

or

Adam Cutler 
The Trout Group, LLC
(646) 378-2936 
CymaBay@troutgroup.com

Source: CymaBay Therapeutics

Released October 15, 2014